| Not Yet Recruiting | Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Pr NCT07481500 | Jakkrit Juhong | N/A |
| Not Yet Recruiting | Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal V NCT07501052 | Sam Chun Dang Pharm. Co. Ltd. | Phase 2 |
| Enrolling By Invitation | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic So NCT07456826 | Harrow Inc | Phase 4 |
| Enrolling By Invitation | AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma NCT07318428 | Inje University | N/A |
| Not Yet Recruiting | Wide Field OCTA in Ocular Diseases NCT07298174 | IRCCS San Raffaele | — |
| Recruiting | Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein O NCT07259928 | Annexin Pharmaceuticals AB | Phase 2 |
| Recruiting | Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium NCT04008121 | MediBeacon | EARLY_Phase 1 |
| Recruiting | Effect of Video Viewing on Intravitreal Injection Experience NCT07002372 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular NCT06439576 | Hoffmann-La Roche | — |
| Not Yet Recruiting | Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy NCT06343961 | Jie Zhong | N/A |
| Unknown | Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients NCT06572553 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO NCT06176963 | Samsung Bioepis Co., Ltd. | Phase 2 |
| Completed | A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and t NCT06495203 | Bayer | — |
| Unknown | OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Reti NCT06332690 | IRCCS Multimedica | — |
| Unknown | Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion NCT04140448 | Renmin Hospital of Wuhan University | — |
| Unknown | Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol NCT06262737 | University Hospital, Clermont-Ferrand | — |
| Unknown | Artificial Intelligence Diagnostic Aid NCT05675540 | Guy's and St Thomas' NHS Foundation Trust | — |
| Active Not Recruiting | Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema NCT07106268 | Tianjin Medical University Eye Hospital | — |
| Completed | Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images NCT06213896 | Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi | — |
| Active Not Recruiting | A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products NCT05476926 | Hoffmann-La Roche | — |
| Completed | Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion NCT05532735 | Annexin Pharmaceuticals AB | Phase 2 |
| Unknown | Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results) NCT05496530 | Benha University | N/A |
| Completed | Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion NCT05532475 | Kasr El Aini Hospital | — |
| Unknown | Anti-VEGF in Real-world NCT05222633 | Wenbin Wei | — |
| Unknown | High Resolution Optical Coherence Tomography NCT05130385 | Insel Gruppe AG, University Hospital Bern | — |
| Active Not Recruiting | VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases NCT05099094 | Shanghai BDgene Co., Ltd. | EARLY_Phase 1 |
| Completed | Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular E NCT05003258 | Assiut University | N/A |
| Terminated | Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment NCT04707625 | Wake Forest University Health Sciences | Phase 4 |
| Unknown | NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients NCT05133791 | University Medical Center Groningen | Phase 1 |
| Withdrawn | Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study NCT04011358 | Centre Hospitalier Régional d'Orléans | N/A |
| Completed | Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Ve NCT05345808 | Al-Azhar University | N/A |
| Unknown | Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema NCT04847869 | University of Sydney | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients NCT04635800 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injectio NCT04563299 | Retina Vitreous Associates of Florida | Phase 4 |
| Completed | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With M NCT04592419 | Kodiak Sciences Inc | Phase 3 |
| Completed | Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph NCT04723160 | Visionary Intelligence Ltd. | — |
| Completed | Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) o NCT04395859 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Unknown | Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections NCT04142164 | Prim. Prof. Dr. Oliver Findl, MBA | N/A |
| Unknown | Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion NCT04062370 | Sun Yat-sen University | Phase 4 |
| Recruiting | Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease NCT04505618 | Johns Hopkins University | N/A |
| Unknown | Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion NCT04075695 | Renmin Hospital of Wuhan University | — |
| Completed | Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China NCT03908307 | Allergan | Phase 4 |
| Completed | The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion NCT05038072 | Damascus University | N/A |
| Terminated | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokineti NCT03790852 | Kodiak Sciences Inc | Phase 1 |
| Unknown | Post Intravitreal Injection Topical NSAID vs. Patching NCT03918590 | The New York Eye & Ear Infirmary | Phase 4 |
| Unknown | Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study NCT03762226 | University of Leipzig | — |
| Unknown | Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Re NCT03680794 | CHU de Reims | N/A |
| Unknown | Correlation Between the Visual Acuity & the OCT Pattern of Macular Edema Secondary to RVO NCT03489915 | Assiut University | — |
| Terminated | Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Followin NCT03203447 | Clearside Biomedical, Inc. | Phase 3 |
| Completed | Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion NCT06757595 | Zhongnan Hospital | — |
| Unknown | Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondar NCT03391219 | Shahid Beheshti University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) NCT03093701 | Taiwan Liposome Company | Phase 2 |
| Unknown | Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab NCT03056092 | Unity Health Toronto | Phase 4 |
| Unknown | Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept NCT03056079 | Unity Health Toronto | Phase 4 |
| Terminated | Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Follow NCT02980874 | Clearside Biomedical, Inc. | Phase 3 |
| Completed | 30g vs 33g Needle for Intravitreal Injections NCT03038048 | Wills Eye | N/A |
| Completed | Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept NCT02880644 | Centre Hospitalier Intercommunal Creteil | — |
| Completed | Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion NCT06416241 | University of Athens | Phase 4 |
| Completed | Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS NCT02956330 | Clearside Biomedical, Inc. | — |
| Completed | Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning NCT02898480 | University of Aarhus | N/A |
| Completed | Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic NCT02521116 | Medical University of Vienna | N/A |
| Completed | Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion NCT02645747 | Bayer | — |
| Unknown | Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO- NCT03525132 | University Hospital, Grenoble | N/A |
| Unknown | Retinal Thrombosis and Atherosclerosis NCT02257333 | University of Roma La Sapienza | — |
| Completed | Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO NCT02503540 | Justis Ehlers | Phase 4 |
| Terminated | SD-OCT Angiography NCT02510885 | Duke University | N/A |
| Completed | Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macul NCT02140411 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection NCT02486484 | Rafic Hariri University Hospital | Phase 2 |
| Completed | Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME. NCT02571972 | Wills Eye | Phase 2 |
| Completed | Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO NCT02387788 | Aerpio Therapeutics | Phase 2 |
| Completed | Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Follow NCT02303184 | Clearside Biomedical, Inc. | Phase 2 |
| Completed | Study of Retinal Oxygenation in Central Retinal Vein Occlusion NCT02523339 | University of Iceland | — |
| Completed | Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX® NCT02181530 | Allergan | — |
| Completed | Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macul NCT02245516 | Kala Pharmaceuticals, Inc. | N/A |
| Completed | Resistance to Antibiotics in Patients Receiving Eye Injections NCT02126423 | Prism Vision Group | — |
| Completed | Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vei NCT02040220 | Bayer | — |
| Completed | A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion NCT01918371 | Allergan | — |
| Completed | A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion NCT01903720 | Allergan | Phase 4 |
| Unknown | Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VE NCT01857544 | Tennessee Retina | Phase 4 |
| Completed | Ocular Manifestations in Rheumatic Diseases NCT03753893 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Completed | Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion NCT02614937 | Ohr Pharmaceutical Inc. | Phase 1 / Phase 2 |
| Completed | Ozurdex for Retinal Vein Occlusion Study (ORVO Study) NCT01790685 | Johns Hopkins University | Phase 2 / Phase 3 |
| Terminated | Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imagin NCT01717937 | University of California, San Francisco | — |
| Terminated | Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) NCT01875770 | Johns Hopkins University | — |
| Completed | Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO NCT01692938 | Optos, PLC | — |
| Recruiting | National Eye Institute Biorepository for Retinal Diseases NCT01496625 | National Eye Institute (NEI) | — |
| Unknown | Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions ( NCT01635803 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 / Phase 3 |
| Completed | Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamet NCT01580020 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion NCT01809236 | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 |
| Completed | A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlu NCT01571557 | Allergan | — |
| Completed | Minocycline to Treat Branch Retinal Vein Occlusion NCT01468831 | National Eye Institute (NEI) | Phase 1 / Phase 2 |
| Completed | A Long-Term Safety Study of OZURDEX® in Clinical Practice NCT01539577 | Allergan | — |
| Completed | Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF NCT02118831 | California Retina Consultants | Phase 1 / Phase 2 |
| Completed | Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema S NCT01566526 | Allergan | — |
| Completed | Minocycline to Treat Central Retinal Vein Occlusion NCT01468844 | National Eye Institute (NEI) | Phase 1 / Phase 2 |
| Completed | Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion NCT01618266 | Allergan | — |
| Completed | Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion NCT01427751 | Allergan | Phase 4 |
| Completed | Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injection NCT01449682 | Retina Macula Institute | Phase 3 |
| Completed | Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusi NCT01568021 | Allergan | — |
| Completed | Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion NCT01428388 | Barnes Retina Institute | N/A |
| Unknown | Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion NCT01581151 | Brian Burke, MPH | N/A |
| Completed | Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO) NCT01411696 | Allergan | — |
| Completed | DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO) NCT01662518 | Centro de Pesquisa Rubens Siqueira | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion NCT01377597 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting NCT01318941 | Novartis Pharmaceuticals | — |
| Completed | Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea NCT01976650 | Allergan | — |
| Terminated | Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) NCT01225146 | David M. Brown, M.D. | Phase 1 |
| Completed | Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion NCT01198327 | Peter A Campochiaro, MD | Phase 3 |
| Terminated | Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina NCT02088151 | Insel Gruppe AG, University Hospital Bern | N/A |
| Completed | Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium NCT01573572 | Bausch & Lomb Incorporated | Phase 4 |
| Completed | Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO NCT01027650 | Allergan | Phase 1 / Phase 2 |
| Completed | Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions NCT01003106 | Peter A Campochiaro, MD | Phase 1 / Phase 2 |
| Unknown | Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion NCT01011374 | Retina Associates of Cleveland, Inc | Phase 1 |
| Completed | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Ve NCT01012973 | Bayer | Phase 3 |
| Completed | Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to NCT00970957 | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | Phase 3 |
| Unknown | Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occ NCT01123564 | University of Pecs | Phase 2 |
| Terminated | Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina NCT00770770 | Alimera Sciences | Phase 2 |
| Completed | Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations NCT00831350 | Barnes Retina Institute | Phase 2 |
| Completed | Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO) NCT00942864 | Novartis Korea Ltd. | Phase 3 |
| Completed | An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Ve NCT01442064 | Genentech, Inc. | N/A |
| Completed | Transcorneal Electrical Stimulation Therapy for Retinal Disease NCT00804102 | Okuvision GmbH | N/A |
| Completed | Ranibizumab in Patients With Branch Retinal Vein Occlusion NCT01027481 | Medical University of Vienna | Phase 4 |
| Unknown | Atorvastatin for the Treatment of Retinal Vein Occlusion NCT00517257 | University of Toronto | Phase 3 |
| Completed | A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch NCT00486018 | Genentech, Inc. | Phase 3 |
| Completed | A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Centra NCT00485836 | Genentech, Inc. | Phase 3 |
| Completed | Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema NCT00403039 | Vitreous -Retina- Macula Consultants of New York | Phase 1 |
| Terminated | Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial NCT00379223 | University Hospital, Bordeaux | N/A |
| Completed | To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusion NCT00493064 | Palo Alto Medical Foundation | Phase 2 / Phase 3 |
| Completed | Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions NCT00407355 | Peter A Campochiaro, MD | Phase 1 / Phase 2 |
| Completed | Combined Triple Procedure in Retinal Vein Occlusion (RVO) NCT00805064 | Johann Wolfgang Goethe University Hospital | Phase 3 |
| Completed | Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage NCT00106132 | National Eye Institute (NEI) | Phase 3 |
| Completed | Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders NCT00101764 | National Eye Institute (NEI) | Phase 1 |
| Completed | A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion NCT00168298 | Allergan | Phase 3 |
| Completed | The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study NCT00105027 | The Emmes Company, LLC | Phase 3 |
| Completed | A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion NCT00168324 | Allergan | Phase 3 |
| Completed | Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondar NCT00088283 | Eyetech Pharmaceuticals | Phase 2 |
| Completed | Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders NCT00071227 | National Eye Institute (NEI) | Phase 1 |
| Completed | Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) NCT00636493 | Glenn Jaffe | EARLY_Phase 1 |
| Terminated | Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion NCT00732927 | Università degli Studi dell'Insubria | Phase 3 |
| Withdrawn | Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.) NCT00211354 | Manhattan Eye, Ear & Throat Hospital | Phase 2 |
| Completed | Central Vein Occlusion Study (CVOS) NCT00000131 | National Eye Institute (NEI) | Phase 3 |